Mechanisms of Decreased Susceptibility to Cefpodoxime in Escherichia coli
Open Access
- 1 December 2002
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 46 (12) , 3829-3836
- https://doi.org/10.1128/aac.46.12.3829-3836.2002
Abstract
Cefpodoxime is one of five antimicrobial agents recommended by the National Committee for Clinical Laboratory Standards for screening isolates of Klebsiella spp. and Escherichia coli for extended-spectrum β-lactamase (ESBL) production. In a prior study, we noted that among 131 E. coli isolates for which the MIC of at least one extended-spectrum cephalosporin (ESC) or aztreonam was ≥2 μg/ml (suggesting the presence of ESBL production), there were 59 isolates (45.0%) for which the MIC of cefpodoxime was 2 to 4 μg/ml (i.e., a positive ESBL screening test), but the MICs of ceftazidime, cefotaxime, and ceftriaxone were ≤1 μg/ml (below the ESBL screening breakpoint). Thus, the results appeared to be false-positive ESBL screening tests. These 59 isolates were divided into five phenotypic groups based on the susceptibility patterns of the organisms to a variety of β-lactam agents and further characterized. The first group (32 isolates) all produced a TEM-1 β-lactamase, and changes in the major outer membrane proteins were detected in representative strains. The second group (18 isolates) lacked blaTEM but showed a number of porin changes; some also showed a modest elevation in production of the AmpC chromosomal β-lactamase. In the third phenotypic group (seven isolates) all expressed an OXA-30 β-lactamase. Some also harbored altered porins. The two remaining phenotypes each had a distinct pattern of porin changes with or without β-lactamase production. These data indicate that several factors are associated with decreased susceptibility to cefpodoxime in E. coli, but none of the mechanisms are related to ESBL production. Current screening methods produced false-positive ESBL results for these isolates. Such isolates should not be classified as containing ESBLs, nor should interpretations of ESCs or aztreonam susceptibility be changed to resistant on test reports for these isolates.Keywords
This publication has 40 references indexed in Scilit:
- Epidemiological Survey of Amoxicillin-Clavulanate Resistance and Corresponding Molecular Mechanisms in Escherichia coli Isolates in France: New Genetic Features of bla TEM GenesAntimicrobial Agents and Chemotherapy, 2000
- β-Lactamases in Shigella flexneri Isolates from Hong Kong and Shanghai and a Novel OXA-1-Like β-Lactamase, OXA-30Antimicrobial Agents and Chemotherapy, 2000
- Complete Sequence of a β-Lactamase-Encoding Plasmid in Neisseria meningitidisAntimicrobial Agents and Chemotherapy, 2000
- Mutations in theampCpromoter ofEscherichia coliisolates resistant to oxyiminocephalosporins without extended spectrum β-lactamase productionFEMS Microbiology Letters, 1999
- Osmoregulatory expression of the ompC gene in Escherichia coli K-12; IS1 insertion in the upstream regulatory region results in constitutive activation of the promoterFEMS Microbiology Letters, 1990
- Reduced Expression of Outer-membrane Proteins in -Lactam-resistant Mutants of Enterobacter cloacaeMicrobiology, 1987
- Loss of OmpC Porin in a Strain of Salmonella typhimurium Causes Increased Resistance to Cephalosporins During TherapyThe Journal of Infectious Diseases, 1987
- Kanamycin-resistant vectors that are analogues of plasmids pUC8, pUC9, pEMBL8 and pEMBL9Gene, 1986
- The ompB locus and the regulation of the major outer membrane porin proteins of Escherichia coli K12Journal of Molecular Biology, 1981
- The Use of Analytical Isoelectric Focusing for Detection and Identification of -LactamasesJournal of General Microbiology, 1975